GE Healthcare Life Sciences wins prestigious bioprocessing industry award
October 24, 2014
CHALFONT ST. GILES, UK – 24 October 2014 – GE Healthcare Life Sciences (NYSE:GE) has won a BioProcess International (BPI) industry award for excellence in bioprocessing facility design. The BPI awards, voted for by bioprocess experts and hosted by industry publication BioProcess International, recognize outstanding products, services, partnerships and people that have had the greatest positive impact across the biopharmaceutical manufacturing industry. The winners were announced at a special ceremony during the 2014 BPI International Conference and Exhibition in Boston, Massachusetts, USA.
GE Healthcare’s winning entry was:
“Excellence in Facility Design or Retrofit” for GE Healthcare and Gallus BioPharmaceuticals1. This award recognises the impressive achievement in the design and delivery of a functional advanced contract manufacturing facility in only nine months.
GE Healthcare was also a finalist in three other categories:
“Excellence in Leadership” for Olivier Loeillot, General Manager, Enterprise Solutions and Commercial BioProcess, Asia, GE Healthcare. This award recognises Olivier’s leadership and drive in bringing innovative modular and flexible manufacturing facilities to the industry. Innovations such as GE Healthcare’s KUBio help biopharmaceutical companies save both time and money whilst increasing speed to market.
“Best Technology Application (Upstream)” for the Xcellerex XDR-50 MO Fermentor. This award recognises the continual advances in single-use technology that have enabled the XDR-50 MO to successfully overcome the challenges of microbial growth in the single-use bioreactor format.
“Most Effective Licensing or Comarketing Agreement” by Promosome LLC and GE Healthcare. This award recognises an industry collaboration focused on harnessing powerful technologies to further increase manufacturing efficiency.
Nigel Darby, Vice President, BioProcess, GE Healthcare Life Sciences, commented: “Winning this award and being a finalist in three other categories is both a great honor and great recognition of the talent, hard work, and commitment to excellence of our GE Healthcare Life Sciences team. This is an exciting industry at the forefront of helping to tackle some of the world’s most challenging diseases, and we are proud to be helping the industry reduce costs and entry barriers and improve efficiency from early-stage research through to full-scale manufacturing. I would like to extend my congratulations to all the finalists, winners and the teams that support them.”
For more information about the winning award and finalists, see the recent press release here.
- Gallus BioPharmaceuticals was recently acquired by DPx Holdings B.V. and now operates under the Patheon business unit. For further information on the acquisition review the recent press release,link.
About GE Healthcare
GE Healthcare provides transformational medical technologies and services to meet the demand for increased access, enhanced quality and more affordable healthcare around the world. GE (NYSE: GE) works on things that matter - great people and technologies taking on tough challenges. From medical imaging, software & IT, patient monitoring and diagnostics to drug discovery, biopharmaceutical manufacturing technologies and performance improvement solutions, GE Healthcare helps medical professionals deliver great healthcare to their patients. For more information about GE Healthcare, visit our website at www.gehealthcare.com.
About BioProcess International Award
The awards celebrate the outstanding achievements, collaborations, business strategies, social corporate responsibility and technology applications that will allow the industry to deliver better, more effective treatments to a global patient base. Organized by BioProcess International (BPI) is a business-to-business publication dedicated to delivering cutting-edge information focused on the development and manufacture of biopharmaceuticals and therapeutics. Learn more at http://www.bioprocessintl.com.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.